Radium-223 Dichloride Should be Used with Caution
By MedImaging International staff writers Posted on 29 Aug 2018 |
The European Medicines Agency (EMA; London, United Kingdom) recommends that use of the novel radiopharmaceutical radium-223 dichloride (Xofigo) in metastasized prostate cancer (PC) should be restricted.
The recommendation, issued by the EMA pharmacovigilance risk assessment committee (PRAC), follows reports of increased deaths and fractures in an ongoing clinical trial, during which patients receiving Xofigo in conjunction with abiraterone acetate and prednisone/prednisolone died 2.6 months earlier on average than those given abiraterone acetate and prednisone/prednisolone together with a placebo. In addition, 29% of patients who received the Xofigo combination suffered fractures, compared with 11% of patients in the placebo group.
PRAC suggests that Xofigo should not be used in patients with no symptoms, or in those with a lower number of osteoblastic bone metastases. The agency also stated that radium-223 dichloride should not be used with other systemic cancer therapies, except for hormone therapies. Patients should also be carefully assessed for risk for fractures before, during, and after treatment, and preventive measures, such as the use of bisphosphonates or denosumab as agents to increase bone strength, should be considered before treatment with Xofigo is started or resumed.
“Patient safety is our top priority. We are therefore unblinding the study to thoroughly analyze the data,” said Mike Devoy, chief medical officer at Bayer, the manufacturer of Xofigo. “It is important to note that, based on available data from previous trials as well as real-world use, the benefit-risk profile of Xofigo in its approved indication remains favorable.”
Xofigo is a drug designed to treat advanced castration-resistant PC by binding with minerals to deliver radiation directly to metastatic bone tumors, limiting the damage to the surrounding normal tissues. It is not recommended that patients taking Xofigo should undergo chemotherapy at the same time, as the combination of drugs can cause bone marrow activity to decrease, resulting in fewer red blood cells, white blood cells, and platelets.
Related Links:
European Medicines Agency
The recommendation, issued by the EMA pharmacovigilance risk assessment committee (PRAC), follows reports of increased deaths and fractures in an ongoing clinical trial, during which patients receiving Xofigo in conjunction with abiraterone acetate and prednisone/prednisolone died 2.6 months earlier on average than those given abiraterone acetate and prednisone/prednisolone together with a placebo. In addition, 29% of patients who received the Xofigo combination suffered fractures, compared with 11% of patients in the placebo group.
PRAC suggests that Xofigo should not be used in patients with no symptoms, or in those with a lower number of osteoblastic bone metastases. The agency also stated that radium-223 dichloride should not be used with other systemic cancer therapies, except for hormone therapies. Patients should also be carefully assessed for risk for fractures before, during, and after treatment, and preventive measures, such as the use of bisphosphonates or denosumab as agents to increase bone strength, should be considered before treatment with Xofigo is started or resumed.
“Patient safety is our top priority. We are therefore unblinding the study to thoroughly analyze the data,” said Mike Devoy, chief medical officer at Bayer, the manufacturer of Xofigo. “It is important to note that, based on available data from previous trials as well as real-world use, the benefit-risk profile of Xofigo in its approved indication remains favorable.”
Xofigo is a drug designed to treat advanced castration-resistant PC by binding with minerals to deliver radiation directly to metastatic bone tumors, limiting the damage to the surrounding normal tissues. It is not recommended that patients taking Xofigo should undergo chemotherapy at the same time, as the combination of drugs can cause bone marrow activity to decrease, resulting in fewer red blood cells, white blood cells, and platelets.
Related Links:
European Medicines Agency
Latest Nuclear Medicine News
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure
- New PET Radiotracer Aids Early, Noninvasive Detection of Inflammatory Bowel Disease
- Combining Amino Acid PET and MRI Imaging to Help Treat Aggressive Brain Tumors